Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3GTAL)

Drug Name
Maribavir Drug Info
Synonyms
176161-24-3; Benzimidavir; (2S,3S,4R,5S)-2-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 1263W94; UNII-PTB4X93HE1; PTB4X93HE1; 5,6-Dichloro-2-(isopropylamino)-1-(beta-L-ribofuranosyl)-1H-benzimidazole; 5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine; (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol; Maribavir [USAN:INN:BAN]; Camvia; C15H19Cl2N3O4; Camvia(TM); Camvia (TN); Bzurea
Cross-matching ID
PubChem CID
471161
ChEBI ID
CHEMBL515408
CAS Number
CAS 176161-24-3
TTD Drug ID
D07WXI
INTEDE Drug ID
DR1896

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Asthma 2.30 0.00e+0 25/31 (80.65%) CD40;TNF;HLA-DQB1;...
Allograft rejection 2.29 0.00e+0 32/38 (84.21%) GZMB;CD40;TNF;...
DNA replication 2.12 3.96e-3 34/36 (94.44%) RFC2;RFC5;FEN1;...
Graft-versus-host disease 1.99 5.94e-3 32/42 (76.19%) GZMB;TNF;HLA-DQB1;...
Mucin type O-glycan biosynthesis 1.96 1.19e-2 20/36 (55.56%) GALNT3;GALNT7;ST6GALNAC2;...
Mismatch repair 1.92 1.19e-2 22/23 (95.65%) RFC2;RFC5;POLD4;...
Type I diabetes mellitus 1.89 1.36e-2 38/43 (88.37%) GZMB;GAD1;TNF;...
Base excision repair 1.84 1.63e-2 29/33 (87.88%) FEN1;APEX1;POLD4;...
Nucleotide excision repair 1.82 1.58e-2 40/47 (85.11%) RFC2;RAD23B;RFC5;...
Autoimmune thyroid disease 1.75 3.33e-2 46/53 (86.79%) GZMB;CD40;HLA-DQB1;...
Systemic lupus erythematosus 1.72 4.97e-2 45/135 (33.33%) CD40;TNF;HLA-DQB1;...
Apoptosis 1.71 4.95e-2 126/168 (75%) BCL2A1;CTSS;GZMB;...
Epithelial cell signaling in Helicobacter pylori infect... 1.70 4.93e-2 62/70 (88.57%) SRC;PAK1;MET;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H